Risk Factors for Lactic Acidosis in HIV-Infected Patients Treated with Nucleoside Reverse-Transcriptase Inhibitors: A Case-Control Study
A case-control study was undertaken to determine risk factors for lactic acidosis in human immunodeficiancy virus-infected patients treated with nucleoside reverse-transcriptase inhibitors (NRTIs). From May 1996 to June 2000, 9 patients with lactic acidosis (defined as a plasma lactic acid level of...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2003-05, Vol.36 (10), p.1324-1328 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1328 |
|---|---|
| container_issue | 10 |
| container_start_page | 1324 |
| container_title | Clinical infectious diseases |
| container_volume | 36 |
| creator | Bonnet, F. Bonarek, M. Morlat, P. Mercié, P. Dupon, M. Gemain, M. C. Malvy, D. Bernard, N. Pellegrin, J. L. Beylot, J. |
| description | A case-control study was undertaken to determine risk factors for lactic acidosis in human immunodeficiancy virus-infected patients treated with nucleoside reverse-transcriptase inhibitors (NRTIs). From May 1996 to June 2000, 9 patients with lactic acidosis (defined as a plasma lactic acid level of >5 mM and plasma pH of |
| doi_str_mv | 10.1086/374601 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_18869147</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4483503</jstor_id><oup_id>10.1086/374601</oup_id><sourcerecordid>4483503</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-69d96793fcff74535d1f2e0b29e8025e87febe7d7c0b4e3173a91a4d9ce3af533</originalsourceid><addsrcrecordid>eNp10VFv0zAQB_AIgdgY8AkQMg_wFrDjOHZ4KxVdi6qBtoIQL5brnDVvaVJ8DrBvwMfGUar1iSef7n46y39n2XNG3zKqqndclhVlD7JTJrjMK1Gzh6mmQuWl4uoke4J4QyljiorH2QkrEpeKnmZ_Lz3ekoWxsQ9IXB_IOtXekpn1TY8eie_IcvUtX3UObISGfDHRQxeRbAKYsfHbx2tyMdgWkm-AXMIvCAj5JpgObfD7aBDIqrv2Wz_e8p7MyDy18nnfxdC35CoOzd3T7JEzLcKzw3mWfV183MyX-frz-Wo-W-e2FDzmVd3Ulay5s87J1BENcwXQbVGDooUAJR1sQTbS0m0JnEluambKprbAjROcn2Vvpr370P8cAKPeebTQtqaDfkDNlKpqVsojtKFHDOD0PvidCXeaUT1mrqfME3x52Dhsd9Ac2SHkBF4fgEFrWpdysR6PrlRC8mJ0rybXD_v_X_ZiMjeYsrxXZfplQcfX5dPYY4Q_92MTbnUluRR6-f2HLi7Up8X51QfN-T-IdKwK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18869147</pqid></control><display><type>article</type><title>Risk Factors for Lactic Acidosis in HIV-Infected Patients Treated with Nucleoside Reverse-Transcriptase Inhibitors: A Case-Control Study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>JSTOR Archive Collection A-Z Listing</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Bonnet, F. ; Bonarek, M. ; Morlat, P. ; Mercié, P. ; Dupon, M. ; Gemain, M. C. ; Malvy, D. ; Bernard, N. ; Pellegrin, J. L. ; Beylot, J.</creator><creatorcontrib>Bonnet, F. ; Bonarek, M. ; Morlat, P. ; Mercié, P. ; Dupon, M. ; Gemain, M. C. ; Malvy, D. ; Bernard, N. ; Pellegrin, J. L. ; Beylot, J.</creatorcontrib><description>A case-control study was undertaken to determine risk factors for lactic acidosis in human immunodeficiancy virus-infected patients treated with nucleoside reverse-transcriptase inhibitors (NRTIs). From May 1996 to June 2000, 9 patients with lactic acidosis (defined as a plasma lactic acid level of >5 mM and plasma pH of <7.38) were identified. Control patients were randomly selected from among a large cohort of patients who initiated a dual NRTI regimen in 1996 or after. Two factors were associated with an increased risk of lactic acidosis: first, a creatinine clearance of <70 mL/min before lactic acidosis (OR, 15.8 [range, 3.0–86.5], P < 10-4), and, second, a low nadir CD4+ T lymphocyte count before the inception of NRTI therapy (OR, 8.4 [range, 1.2–∞], P = .03). The total cumulative exposure to NRTIs was not associated with an increased risk of lactic acidosis, nor was the cumulative exposure to any of the 4 NRTIs studied. According to these results, monitoring of creatinine clearance, especially in patients with a low nadir CD4+ T lymphocyte count, could lead to modifications in antiretroviral therapy in order to diminish the risk of occurrence of lactic acidosis.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/374601</identifier><identifier>PMID: 12746780</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Acidosis, Lactic - chemically induced ; Acidosis, Lactic - epidemiology ; Adult ; Antiretrovirals ; Biological and medical sciences ; Case-Control Studies ; Didanosine - adverse effects ; Didanosine - therapeutic use ; Drug toxicity and drugs side effects treatment ; Female ; Hepatitis B ; HIV ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV/AIDS ; Human viral diseases ; Humans ; Infections ; Infectious diseases ; Kidney failure ; Lactic acidosis ; Male ; Medical sciences ; Middle Aged ; Miscellaneous (drug allergy, mutagens, teratogens...) ; Nadir ; Nucleosides ; Pharmacology. Drug treatments ; Predisposing factors ; Renal clearance ; Reverse Transcriptase Inhibitors - adverse effects ; Reverse Transcriptase Inhibitors - therapeutic use ; Risk Factors ; Stavudine - adverse effects ; Stavudine - therapeutic use ; T lymphocytes ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>Clinical infectious diseases, 2003-05, Vol.36 (10), p.1324-1328</ispartof><rights>Copyright 2003 The Infectious Diseases Society of America</rights><rights>2003 by the Infectious Diseases Society of America 2003</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-69d96793fcff74535d1f2e0b29e8025e87febe7d7c0b4e3173a91a4d9ce3af533</citedby><cites>FETCH-LOGICAL-c453t-69d96793fcff74535d1f2e0b29e8025e87febe7d7c0b4e3173a91a4d9ce3af533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4483503$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4483503$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27924,27925,58017,58250</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14857320$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12746780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bonnet, F.</creatorcontrib><creatorcontrib>Bonarek, M.</creatorcontrib><creatorcontrib>Morlat, P.</creatorcontrib><creatorcontrib>Mercié, P.</creatorcontrib><creatorcontrib>Dupon, M.</creatorcontrib><creatorcontrib>Gemain, M. C.</creatorcontrib><creatorcontrib>Malvy, D.</creatorcontrib><creatorcontrib>Bernard, N.</creatorcontrib><creatorcontrib>Pellegrin, J. L.</creatorcontrib><creatorcontrib>Beylot, J.</creatorcontrib><title>Risk Factors for Lactic Acidosis in HIV-Infected Patients Treated with Nucleoside Reverse-Transcriptase Inhibitors: A Case-Control Study</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>A case-control study was undertaken to determine risk factors for lactic acidosis in human immunodeficiancy virus-infected patients treated with nucleoside reverse-transcriptase inhibitors (NRTIs). From May 1996 to June 2000, 9 patients with lactic acidosis (defined as a plasma lactic acid level of >5 mM and plasma pH of <7.38) were identified. Control patients were randomly selected from among a large cohort of patients who initiated a dual NRTI regimen in 1996 or after. Two factors were associated with an increased risk of lactic acidosis: first, a creatinine clearance of <70 mL/min before lactic acidosis (OR, 15.8 [range, 3.0–86.5], P < 10-4), and, second, a low nadir CD4+ T lymphocyte count before the inception of NRTI therapy (OR, 8.4 [range, 1.2–∞], P = .03). The total cumulative exposure to NRTIs was not associated with an increased risk of lactic acidosis, nor was the cumulative exposure to any of the 4 NRTIs studied. According to these results, monitoring of creatinine clearance, especially in patients with a low nadir CD4+ T lymphocyte count, could lead to modifications in antiretroviral therapy in order to diminish the risk of occurrence of lactic acidosis.</description><subject>Acidosis, Lactic - chemically induced</subject><subject>Acidosis, Lactic - epidemiology</subject><subject>Adult</subject><subject>Antiretrovirals</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Didanosine - adverse effects</subject><subject>Didanosine - therapeutic use</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Female</subject><subject>Hepatitis B</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV/AIDS</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Kidney failure</subject><subject>Lactic acidosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Miscellaneous (drug allergy, mutagens, teratogens...)</subject><subject>Nadir</subject><subject>Nucleosides</subject><subject>Pharmacology. Drug treatments</subject><subject>Predisposing factors</subject><subject>Renal clearance</subject><subject>Reverse Transcriptase Inhibitors - adverse effects</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>Risk Factors</subject><subject>Stavudine - adverse effects</subject><subject>Stavudine - therapeutic use</subject><subject>T lymphocytes</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10VFv0zAQB_AIgdgY8AkQMg_wFrDjOHZ4KxVdi6qBtoIQL5brnDVvaVJ8DrBvwMfGUar1iSef7n46y39n2XNG3zKqqndclhVlD7JTJrjMK1Gzh6mmQuWl4uoke4J4QyljiorH2QkrEpeKnmZ_Lz3ekoWxsQ9IXB_IOtXekpn1TY8eie_IcvUtX3UObISGfDHRQxeRbAKYsfHbx2tyMdgWkm-AXMIvCAj5JpgObfD7aBDIqrv2Wz_e8p7MyDy18nnfxdC35CoOzd3T7JEzLcKzw3mWfV183MyX-frz-Wo-W-e2FDzmVd3Ulay5s87J1BENcwXQbVGDooUAJR1sQTbS0m0JnEluambKprbAjROcn2Vvpr370P8cAKPeebTQtqaDfkDNlKpqVsojtKFHDOD0PvidCXeaUT1mrqfME3x52Dhsd9Ac2SHkBF4fgEFrWpdysR6PrlRC8mJ0rybXD_v_X_ZiMjeYsrxXZfplQcfX5dPYY4Q_92MTbnUluRR6-f2HLi7Up8X51QfN-T-IdKwK</recordid><startdate>20030515</startdate><enddate>20030515</enddate><creator>Bonnet, F.</creator><creator>Bonarek, M.</creator><creator>Morlat, P.</creator><creator>Mercié, P.</creator><creator>Dupon, M.</creator><creator>Gemain, M. C.</creator><creator>Malvy, D.</creator><creator>Bernard, N.</creator><creator>Pellegrin, J. L.</creator><creator>Beylot, J.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20030515</creationdate><title>Risk Factors for Lactic Acidosis in HIV-Infected Patients Treated with Nucleoside Reverse-Transcriptase Inhibitors: A Case-Control Study</title><author>Bonnet, F. ; Bonarek, M. ; Morlat, P. ; Mercié, P. ; Dupon, M. ; Gemain, M. C. ; Malvy, D. ; Bernard, N. ; Pellegrin, J. L. ; Beylot, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-69d96793fcff74535d1f2e0b29e8025e87febe7d7c0b4e3173a91a4d9ce3af533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Acidosis, Lactic - chemically induced</topic><topic>Acidosis, Lactic - epidemiology</topic><topic>Adult</topic><topic>Antiretrovirals</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Didanosine - adverse effects</topic><topic>Didanosine - therapeutic use</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Female</topic><topic>Hepatitis B</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV/AIDS</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Kidney failure</topic><topic>Lactic acidosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Miscellaneous (drug allergy, mutagens, teratogens...)</topic><topic>Nadir</topic><topic>Nucleosides</topic><topic>Pharmacology. Drug treatments</topic><topic>Predisposing factors</topic><topic>Renal clearance</topic><topic>Reverse Transcriptase Inhibitors - adverse effects</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>Risk Factors</topic><topic>Stavudine - adverse effects</topic><topic>Stavudine - therapeutic use</topic><topic>T lymphocytes</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bonnet, F.</creatorcontrib><creatorcontrib>Bonarek, M.</creatorcontrib><creatorcontrib>Morlat, P.</creatorcontrib><creatorcontrib>Mercié, P.</creatorcontrib><creatorcontrib>Dupon, M.</creatorcontrib><creatorcontrib>Gemain, M. C.</creatorcontrib><creatorcontrib>Malvy, D.</creatorcontrib><creatorcontrib>Bernard, N.</creatorcontrib><creatorcontrib>Pellegrin, J. L.</creatorcontrib><creatorcontrib>Beylot, J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bonnet, F.</au><au>Bonarek, M.</au><au>Morlat, P.</au><au>Mercié, P.</au><au>Dupon, M.</au><au>Gemain, M. C.</au><au>Malvy, D.</au><au>Bernard, N.</au><au>Pellegrin, J. L.</au><au>Beylot, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk Factors for Lactic Acidosis in HIV-Infected Patients Treated with Nucleoside Reverse-Transcriptase Inhibitors: A Case-Control Study</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2003-05-15</date><risdate>2003</risdate><volume>36</volume><issue>10</issue><spage>1324</spage><epage>1328</epage><pages>1324-1328</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>A case-control study was undertaken to determine risk factors for lactic acidosis in human immunodeficiancy virus-infected patients treated with nucleoside reverse-transcriptase inhibitors (NRTIs). From May 1996 to June 2000, 9 patients with lactic acidosis (defined as a plasma lactic acid level of >5 mM and plasma pH of <7.38) were identified. Control patients were randomly selected from among a large cohort of patients who initiated a dual NRTI regimen in 1996 or after. Two factors were associated with an increased risk of lactic acidosis: first, a creatinine clearance of <70 mL/min before lactic acidosis (OR, 15.8 [range, 3.0–86.5], P < 10-4), and, second, a low nadir CD4+ T lymphocyte count before the inception of NRTI therapy (OR, 8.4 [range, 1.2–∞], P = .03). The total cumulative exposure to NRTIs was not associated with an increased risk of lactic acidosis, nor was the cumulative exposure to any of the 4 NRTIs studied. According to these results, monitoring of creatinine clearance, especially in patients with a low nadir CD4+ T lymphocyte count, could lead to modifications in antiretroviral therapy in order to diminish the risk of occurrence of lactic acidosis.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>12746780</pmid><doi>10.1086/374601</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2003-05, Vol.36 (10), p.1324-1328 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_18869147 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; JSTOR Archive Collection A-Z Listing; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Acidosis, Lactic - chemically induced Acidosis, Lactic - epidemiology Adult Antiretrovirals Biological and medical sciences Case-Control Studies Didanosine - adverse effects Didanosine - therapeutic use Drug toxicity and drugs side effects treatment Female Hepatitis B HIV HIV Infections - complications HIV Infections - drug therapy HIV/AIDS Human viral diseases Humans Infections Infectious diseases Kidney failure Lactic acidosis Male Medical sciences Middle Aged Miscellaneous (drug allergy, mutagens, teratogens...) Nadir Nucleosides Pharmacology. Drug treatments Predisposing factors Renal clearance Reverse Transcriptase Inhibitors - adverse effects Reverse Transcriptase Inhibitors - therapeutic use Risk Factors Stavudine - adverse effects Stavudine - therapeutic use T lymphocytes Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
| title | Risk Factors for Lactic Acidosis in HIV-Infected Patients Treated with Nucleoside Reverse-Transcriptase Inhibitors: A Case-Control Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T07%3A02%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20Factors%20for%20Lactic%20Acidosis%20in%20HIV-Infected%20Patients%20Treated%20with%20Nucleoside%20Reverse-Transcriptase%20Inhibitors:%20A%20Case-Control%20Study&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Bonnet,%20F.&rft.date=2003-05-15&rft.volume=36&rft.issue=10&rft.spage=1324&rft.epage=1328&rft.pages=1324-1328&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/374601&rft_dat=%3Cjstor_proqu%3E4483503%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18869147&rft_id=info:pmid/12746780&rft_jstor_id=4483503&rft_oup_id=10.1086/374601&rfr_iscdi=true |